Olivia Vizier

Swiss biopharma startup Aphaia Pharma AG is taking the concept of “location, location, location” to its extreme. The company started dosing patients in a phase II trial of its lead candidate, Aph-012, in late April, 2023. The trial is a randomized, double-blind, placebo-controlled, multicenter proof-of-concept study to evaluate Aph-012’s ability to improve glucose tolerance in […]

Araris Biotech is using this linker technology to develop next-generation ADCs with the potential to be safer and more efficacious for cancer patients. In head-to-head animal model studies against FDA approved ADCs, the ADCs created using Araris’ linker technology demonstrated improved efficacy, even at low doses, as well as high tolerability.

Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, they were the first vectors that were developed for gene therapy delivery. A plethora of viral vectors entered the gene therapy arena including lentiviruses, retroviruses, herpes simplex viruses, adenoviruses and adeno-associated viruses. Each of these vector

Tumor-infiltrating myeloid cells such as tumor-associated macrophages (TAMs) can suppress T-cell recruitment and function and promote the expansion and dissemination of cancer cells depending on their functional states. In hepatocellular carcinoma (HCC), TAMs are associated with resistance to sorafenib, the first-line treatment for advanced HCC.

Later this year, Umoja Biopharma will open 77,000 square feet of a 146,000 square foot manufacturing facility at the Colorado Technology Center in Louisville. Although Umoja is only in the early clinical stage of developing CAR-T therapeutics, the company got an early start on creating a facility to make the lentiviral vectors that it will

Life Biosciences, a biotech advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury, has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.

Revolo Biotherapeutics’ ‘1104 is designed to reset the immune system “upstream” before the inflammatory cascade occurs.

Ikena has seen no proteinuria in monkey trials, and Manfredi reckons others are now following his company in developing subtype-selective Tead inhibitors to get around toxicity; Sporos’s Tead1/4 inhibitor SPRI-0117 appears to be one of these.

Revolo Biotherapeutics thinks it has the data to keep advancing a would-be challenger to Dupixent. In a small, short phase 2a allergy trial, the biotech linked its peptide to a “numeric reduction” on the primary endpoint, emboldening it to start looking forward to further development.

Our lead anti-infective candidate, RECCE® 327 (R327), will be advancing into a Phase Ia/IIb intravenous multiple ascending dose safety and tolerability study and a Phase II clinical trial investigating the efficacy of R327 against diabetic foot ulcer (DFU) infections.

Life Biosciences’ gene therapy platform works by inducing expression of the transcription factors Oct3/4, Sox2 and Klfr4, or OSK—three of the four Yamanaka factors. When all four Yamanaka factors are expressed together, have been shown to fully reprogram differentiated human, mouse and primate cells back into pluripotent stem cells, erasing their cell identity and resetting

Shares of MindMed surged Friday morning after researchers who have worked with the company unveiled positive results in a trial using LSD to treat major depressive disorder, running a test similar to the biotech’s trials of its own related compound.

As a ‘smart knee’ that transmits data rolls out, medical specialists and engineers predict sensors will be added to artificial hips, shoulders and spinal implants.

eFFECTOR Therapeutics Inc will collaborate with Stanford Medicine on an investigator-initiated randomized Phase 2 study evaluating zotatifin in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a preoperative setting.

Another expert in the space, Emma Harvey, M.D., Global Head of Medical Affairs, F2G, concurred.Harvey focuses on antifungal resistance, a type of antimicrobial resistance that occurs when fungi become resistant to antifungal agents. The results of antifungal resistance on human health are similar to that of AMR, including treatment failures, prolonged illness and even death,

Philipp Spycher, PhD, CEO of Araris Biotech: Since I first started my career on the academic side of the antibody-drug conjugate (ADC) field, I was fascinated by the idea of helping patients by creating more targeted and highly specific drugs.

Revolo Biotherapeutics thinks it has the data to keep advancing a would-be challenger to Dupixent. In a small, short phase 2a allergy trial, the biotech linked its peptide to a “numeric reduction” on the primary endpoint, emboldening it to start looking forward to further development.

Immunome’s Discovery Engine leverages the information stored in memory B cells to guide the discovery of first-in-class antibody therapeutics directed at potentially novel targets in oncology and other areas.

We designed the TFF method to eliminate that problem. The technology generates millimeter-sized droplets that, because of their large size, minimize protein exposure to air–liquid interfaces. Thus, we have observed far less denaturation

Selecta Biosciences and Sobi have laid down a marker in their attempt to challenge Horizon for the gout market, delivering phase 3 data that suggest their SEL-212 candidate can match the efficacy of Krystexxa despite being administered less frequently.

Meanwhile, David Fontana, chief operating officer (COO) at immuno-oncology company Umoja Biopharma, cited Umoja’s partnership with Lupagen as a good example of two companies leveraging each other’s resources, as well as expertise. Last year, the two companies announced a collaboration to evaluate extracorporeal in vivo delivery as a route of administration for Umoja’s VivoVec particles

Elixirgen is developing what it calls self-replicating RNA therapies to treat telomere biology disorders and other conditions.

Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it’s backed to pioneer a new category of genetic medicine it calls gene writing.

Aphaia continues to create additional bead formulations to broaden its product portfolio to potentially enhance treatment efficacy for other metabolic diseases and patient populations in the future.

Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.

When the term “gene therapy” comes up, the first thing that comes to mind is often some sort of gene replacement or gene editing (either a DNA correction or disruption) to treat a well-defined Mendelian genetic disorder like sickle cell disease or phenylketonuria—not some broad, genetic, complex condition like inflammation or osteoarthritis. Well, unless you

“Symptoms depend on the stage of disease and also which organs are affected,” said Dr. Emma Harvey, Global Head of Medical Affairs at the clinical-stage biopharmaceutical company F2G. “It starts as a respiratory disease and can be indistinguishable on symptoms from viral or bacterial pneumonia.”

Akihiro Ko is the CEO and Co-Founder of Elixirgen Therapeutics, which was founded with the mission of treating patients using RNA technology. Their c-srRNA, controllable self-replicating RNA, technology is being applied to telomere biology disorders where patients have inherited short telomeres and a failure to develop bone marrow. Elixirgen is looking to restore the ability

My biggest challenge was financing Canary. I think the concept behind Canary is timely, highly medically relevant, and an obvious next step in the evolution of medical devices—life-saving

John Rex, MD, chief medical officer at drug discovery company F2G, told Becker’s he also feels the solution is two-part: legislative and research-driven.